Objective Diabetic patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] 30–59 mL/min/1.73 m 2) are at particular cardiovascular risk. Fenofibrate's safety in these ...
CLEVELAND, Ohio - A team from University Hospitals Seidman Cancer Center is launching the nation’s first-ever clinical trials evaluating the cholesterol drug fenofibrate (Triglide, Fibricor, Lipofen) ...
Co and AstraZeneca confirmed they will advance the development of ABT's next-generation fenofibrate ABT-335 and AstraZeneca's Crestor in a fixed-dose combination treatment into Phase III clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results